Documents AAV2-NRTN (CERE-120) In Parkinson’s Disease: Phase 2 Trial Results and Path Forward Joao Siffert,....

AAV2-NRTN (CERE-120) In Parkinsonâs Disease: Phase 2 Trial Results and Path Forward Joao Siffert, MD Chief Medical Officer Ceregene, Inc. San Diego, CA ASENT 12th Annual…

Documents AAV2-NRTN (CERE-120) In Parkinson’s Disease: Phase 2 Trial Results and Path Forward

AAV2-NRTN (CERE-120) In Parkinsonâs Disease: Phase 2 Trial Results and Path Forward Joao Siffert, MD Chief Medical Officer Ceregene, Inc. San Diego, CA ASENT 12th Annual…